AdipoGen Life Sciences

PP1

Name: PP1
Brand: AdipoGen Life Sciences
SKU: AG-CR1-3562
Price: 50.00 CHF
Availability: InStock

As low as CHF 50.00

In stock

Only %1 left

AG-CR1-3562-M0011 mgCHF 50.00

AG-CR1-3562-M0055 mgCHF 150.00

Specifications / Handling

More Information
Product Details
Synonyms	4-Amino-5-(methylphenyl)-7-(tert.butyl)pyrazolo-(3,4-d)pyrimidine
Product Type	Chemical
Properties
Formula	C₁₆H₁₉N₅
MW	281.4
CAS	172889-26-8
Purity Chemicals	≥98% (HPLC)
Appearance	White solid.
Solubility	Soluble in DMSO. Slightly soluble in ethanol.
InChi Key	ZVPDNRVYHLRXLX-UHFFFAOYSA-N
Smiles	CC1=CC=C(C=C1)C1=NN(C2=C1C(N)=NC=N2)C(C)(C)C
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
Safety Data Sheet	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Scientific Background Information

Product Description

Highly potent and selective Scr family tyrosine kinase inhibitor [1, 2, 6, 9].
Shows anti-Ras cancer potential by blocking Ras-induced activation of PAK1 [4].
Antitumor compound [3, 4, 5, 7].
RIP2 inhibitor [9].
Blocks TGF-β-mediated cellular responses [8, 10].

Product-specific References

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996)
Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells: M. Amoui, et al.; Eur. J. Immunol. 27, 1881 (1997)
Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1: G.W. Krystal, et al.; Cancer Res. 58, 4660 (1998)
An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies: H. He, et al.; Cancer J. 6, 243 (2000)
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes: F. Carlomagno, et al.; Cancer Res. 62, 1077 (2002)
The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases: L. Tatton, et al.; J. Biol. Chem. 278, 4847 (2003)
Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II: M. Maeda, et al.; J. Biol. Chem. 281, 59 (2006)
The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)
The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011)

Call	+41 61 926 6040
Fax	+41 61 926 6049